SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
PHAT reported Third Quarter 2026 results. The stock moved -1.0% on the print.
PHATearnings

Earnings reactions, page 9

Phathom Pharmaceuticals, Inc. (PHAT) Q3 FY2026 earnings

October 29, 2026 · SharpeIQ Research Desk

Reported results

  • Net revenues for the third quarter 2026 were $84.7 million, compared to $49.5 million for the third quarter 2025.
  • GAAP net loss for the third quarter 2026 was $13.9 million, compared to $30.0 million for the third quarter 2025.
  • Non-GAAP adjusted net income for the third quarter 2026 was $3.0 million, compared to a non-GAAP adjusted net loss of $11.2 million for the same period in 2025.
  • Non-GAAP operating expenses, excluding stock-based compensation, were $60.5 million for the third quarter 2026, compared to $49.3 million for the third quarter 2025.
  • Approximately 380,000 total VOQUEZNA prescriptions were filled during the third quarter 2026.

Guidance

  • Full-year 2026 net revenue: $310–325 million
  • Full-year 2026 gross-to-net discount: 55–59%
  • Full-year 2026 gross margin: ~80%
  • Full-year 2026 non-GAAP operating expenses, excluding stock-based compensation: $235–245 million

Price and volatility reaction

The stock moved -1.0% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -46.0 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release6.282026-10-28
Close after release6.222026-10-29
Realised move-1.0%close to close
30d ATM IV change-46.0 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →